8-KFiled Jul 20, 8:00 PM ET

Virtuix Holdings Amends Warrants, Lowers Exercise Price to $2.50

$VTIX · Virtuix Holdings Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Virtuix Holdings Amends Warrants, Lowers Exercise Price to $2.50

What Happened
Virtuix Holdings, Inc. (VTIX) filed an 8-K on July 21, 2026 announcing amendments to three warrants held by Streeterville Capital, LLC that reduce the warrant exercise price to $2.50 per share for a defined period and extend the warrants’ term. The amendments apply to the Equity Financing Warrant (Securities Purchase Agreement dated Aug 25, 2025), the Second Debt Financing Warrant (Oct 30, 2025) and the Third Debt Financing Warrant (Dec 19, 2025). The Reduced Exercise Price Period begins July 21, 2026 and runs through August 27, 2026, with automatic one‑month extensions possible.

Key Details

  • Reduced exercise price: $2.50 per Warrant share during the Reduced Exercise Price Period (previously reduced to $3.00).
  • Effective/filing date: July 21, 2026; Reduced Exercise Price Period initially through August 27, 2026.
  • Extensions: Expiration date and reduced-price period automatically extend for up to four additional consecutive one‑month periods unless the Board’s Special Committee opts not to extend.
  • Termination/right to revert: The company may end the Reduced Exercise Price Period on two trading days’ notice, after which the exercise price reverts to the original Nasdaq Valuation Price per each warrant; all other warrant terms remain unchanged.

Why It Matters
Lowering the warrant exercise price makes it cheaper for Streeterville Capital to convert warrants into Class A common stock during the Reduced Exercise Price Period, which could increase potential dilution if exercised. The extension mechanics (automatic monthly extensions up to four times) and the company’s ability to terminate the reduced-price window on short notice affect timing and certainty around potential share issuance. Investors should note the specific dates, the reversion mechanism to the Nasdaq Valuation Price, and that these changes only modify exercise price and timing—not other warrant terms.